January 24, 2018
Authors Julie Bertrand (1), Aurélie Barrail-Tran (2), Rada Savic (3), Alain Pruvost (4), Anne-Marie Taburet (2), France Mentré (1), Céline Verstuyft (5) and the ANRS 134-COPHAR 3 trial group
Affiliations (1) UMR 1137 IAME INSERM Université Paris Diderot, (2) AP-HP, Hôpital Bicêtre, Pharmacie Clinique; Université Paris Sud ; INSERM UMR 1184, Center for Immunology of Viral Infections and Autoimmune Diseases, (3) Department of Bioengineering and Therapeutic Sciences, University of California San Francisco (4) Service de Pharmacologie et d’Immunoanalyse (SPI), plateforme SMArt-MS, CEA, INRA, Université Paris-Saclay, 91191, Gif sur Yvette, France, (5) Service de génétique moléculaire et pharmacogénétique, hôpital Bicêtre, AP-HP; Université Paris Sud; INSERM UMR 1184, Center for Immunology of Viral Infections and Autoimmune Diseases
Presentation type Oral
Presenters Julie Bertrand
Tenofovir (TFV) and emtricitabine (FTC), which are part of the recommended highly active antiretroviral therapy for naïve HIV patients, show a large inter-individual pharmacokinetic (PK) variability so far unexplained. We model the concentrations of plasma TFV and FTC and their intracellular metabolites (TFV-DP and FTC-TP) collected after 4 and 24 weeks of treatment in 34 […]
